Our Science and Technology
Rooted in a Deep Understanding of Genetics
The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact.
WHO WE ARE
Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.
Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them.

We have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders to rare diseases and beyond.
We push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world.

We believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world.
JOIN OUR TEAM
Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us.

– Second major approval for WAINZUA, which is marketed in the U.S. as WAINUA™ – – EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo – CARLSBAD, Calif.
CARLSBAD, Calif. --(BUSINESS WIRE)--Feb. 25, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46 th Annual Institutional Investors Conference on Tuesday, March 4, 2025 TD Cowen
<p>– Data also show significant and clinically meaningful improvements in quality-of-life measures in new analyses from Phase 3 and Phase 2 clinical program – –With a PDUFA date of August 21, 2025 , donidalorsen positioned to be Ionis’ second independent commercial launch – CARLSBAD, Calif.</p>